Skip to main content
. 2020 Apr 8;72(10):1709–1715. doi: 10.1093/cid/ciaa327

Table 2.

Severity of Reported Adverse Eventsa

Ethambutol (n = 28) Ethionamide (n = 36)
Adverse Event Grade 1 (n = 24) Grade 2 (n = 4) Grade 1 (n = 29) Grade 2 (n = 7) Total Adverse Events (n = 64)
Vertigo/dizziness 8 (42) 0 (0) 11 (58) 0 (0) 19 (30)
Vomiting 4 (36) 0 (0) 6 (55) 1 (9) 11 (17)
Anxiety 0 (0) 2 (20) 2 (20) 6 (60) 10 (16)
Nausea 4 (50) 0 (0) 4 (50) 0 (0) 8 (13)
Arthralgia 3 (100) 0 (0) 0 (0) 0 (0) 3 (4)
Pain 2 (67) 0 (0) 1 (33) 0 (0) 3 (4)
Abdominal distention 1 (100) 0 (0) 0 (0) 0 1 (2)
Bloating 0 (0) 0 (0) 1 (100) 0 (0) 1 (2)
Cough 1 (100) 0 (0) 0 (0) 0 (0) 1 (2)
Disturbed menstruation 0 (0) 0 (0) 1 (100) 0 (0) 1 (2)
Fatigue 1 (100) 0 (0) 0 (0) 0 (0) 1 (2)
Headache 0 (0) 0 (0) 1 (100) 0 (0) 1 (2)
Insomnia 0 (0) 0 (0) 1 (100) 0 (0) 1 (2)
Myalgia 0 (0) 0 (0) 1 (100) 0 (0) 1 (2)
Polyuria 0 (0) 1 (100) 0 (0) 0 (0) 1 (2)
Yellow discoloration of skin 0 (0) 1 (100) 0 (0) 0 (0) 1 (2)

Data are presented as no. (row %).

aThere were no grade 3 or 4 adverse events.